Table 1.
Clinicopathological features
| BCS/OBCI | OBCII | p value | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Entire cohort | 2880 | 91 | 297 | 9 | |
| Age (yr) | 2879 | 58 [49-68] | 297 | 54 [46-63] | <0.001 |
| Invasive cancer | 2673 | 93 | 260 | 88 | 0.0012 |
| Lobular histology | 189 | 7 | 21 | 7 | 0.7372 |
| NAC | 441 | 16 | 65 | 25 | 0.0032 |
| Tumor size (mm)* | 379 | 30 [23-40] | 41 | 30 [23-43] | 0.4515 |
| cT1/2* | 363 | 86 | 34 | 77 | 0.1099 |
| Radiotherapy | 2652 | 92 | 293 | 98 | <0.001 |
| Radiotherapy boost | 2033 | 70 | 197 | 66 | 0.1264 |
| Endocrine therapy | 1927 | 67 | 196 | 66 | 0.7494 |
| Chemotherapy | 1752 | 61 | 186 | 63 | 0.5464 |
Categorical variables are presented as counts (%) and continuous ones as medians (IQR)
Statistically significant values are indicated in bold
*Refers to patients treated with neoadjuvant chemotherapy only
BCS conventional breast-conserving surgery (Tübingen 1-2); OBCI oncoplastic breast-conserving surgery level I (Clough level I/Tübingen 3-4); OBCII oncoplastic breast-conserving surgery (Clough level II/Tübingen 5-6); NAC neoadjuvant chemotherapy